| scholarly article | Q13442814 |
| P50 | author | Josep Tabernero Caturla | Q37387600 |
| P2093 | author name string | Andrew H Ko | |
| S Gail Eckhardt | |||
| Andrea Pirzkall | |||
| Manuel Hidalgo | |||
| Patricia LoRusso | |||
| David E Gerber | |||
| Jordan D Berlin | |||
| Christopher H Lieu | |||
| Andres Cervantes | |||
| Bruce McCall | |||
| J Paul Eder | |||
| Amy V Kapp | |||
| Anne Uyei | |||
| Amy Tsuhako | |||
| P2860 | cites work | ErbB receptors and signaling pathways in cancer | Q37390082 |
| Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). | Q39187965 | ||
| Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling | Q39252593 | ||
| MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors | Q39355055 | ||
| Somatic activation of the K-ras oncogene causes early onset lung cancer in mice | Q40809826 | ||
| ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation | Q24621754 | ||
| Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 | Q24633878 | ||
| Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3 | Q27646596 | ||
| Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. | Q27852991 | ||
| The cellular response to neuregulins is governed by complex interactions of the erbB receptor family | Q28609130 | ||
| Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions | Q28609149 | ||
| EGFR antagonists in cancer treatment | Q29616740 | ||
| Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer | Q29618030 | ||
| The HER family and cancer: emerging molecular mechanisms and therapeutic targets | Q34558080 | ||
| Targeting the function of the HER2 oncogene in human cancer therapeutics | Q34766486 | ||
| The ErbB receptors and their role in cancer progression. | Q35089324 | ||
| Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer | Q35671281 | ||
| Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells | Q35691935 | ||
| Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition | Q37331610 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1024-e89 | |
| P577 | publication date | 2017-06-07 | |
| P1433 | published in | Oncologist | Q2122327 |
| P1476 | title | A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS | |
| P478 | volume | 22 |
Search more.